Market Overview

UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook

Share:
Related PCRX
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
Aratana Therapeutics Announces Positive Pivotal Results for AT-003
Pacira Missed Q2 Earnings and Revenues, Exparel in Focus - Analyst Blog (Zacks)

Wedbush maintained Pacira Pharmaceuticals (NASDAQ: PCRX) with an Outperform rating and raised the price target from $23.00 to $32.00.

Wedbush said, "As already preannounced, PCRX reported Q4 EXPAREL sales of $7.8MM, ahead of our original $7.0MM estimate. Q4 total revenues were $10.5MM and GAAP EPS loss was ($0.50) versus our ($0.32) and Street's ($0.42) estimates. The company ended Q4 with about $42.6MM in cash and including proceeds from the January convertible debt offering, we estimate current cash of about $123MM. We project runway well into potential profitability, which we model to occur in 2014."

Pacira Pharmaceuticals closed at $25.30 on Wednesday.

Latest Ratings for PCRX

DateFirmActionFromTo
Jul 2015Bank of AmericaUpgradesUnderperformNeutral
Jul 2015Leerink SwannMaintainsMarket Perform
Jul 2015BarclaysMaintainsOverweight

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Get Benzinga's Newsletters